AZITHROMYCIN (azithromycin) by Entera Bio is drug. First approved in 2006.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
Azithromycin is a macrolide antibiotic administered via injection for bacterial infections. It works by inhibiting bacterial protein synthesis through binding to the ribosome. The injectable formulation serves patients requiring parenteral antimicrobial therapy.
Moderate competitive pressure (30%) suggests a mature market with consolidation; commercial teams should expect right-sizing as LOE approaches.
drug. [see Microbiology ()]
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial
Azithromycin as Adjunctive Treatment for Uncomplicated Severe Acute Malnutrition
Erythromycin Versus Azithromycin for Preterm Prelabor Rupture of Membranes
Optimising Azithromycin Prevention Treatment in COPD to Reduce Exacerbations
Azithromycin Before Induction
Worked on AZITHROMYCIN at Entera Bio? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on azithromycin injectable offers experience in mature generic product management, supply chain optimization, and regulatory compliance rather than commercial expansion. This role is ideal for professionals focused on operational excellence, cost management, and healthcare system relationships in a highly commoditized therapeutic area.